Home » Stocks » Prelude Therapeutics

Prelude Therapeutics, Inc. (PRLD)

Stock Price: $29.33 USD 0.31 (1.07%)
Updated Oct 21, 2020 3:03 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 1.25B
Revenue (ttm) n/a
Net Income (ttm) -37.69M
Shares Out 42.45M
EPS (ttm) -0.89
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 21, 2020
Last Price $29.33
Previous Close $29.02
Change ($) 0.31
Change (%) 1.07%
Day's Open 29.19
Day's Range 29.11 - 30.76
Day's Volume 173,300
52-Week Range 23.69 - 50.19

More Stats

Market Cap 1.25B
Enterprise Value 1.22B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 42.45M
Float 37.74M
EPS (basic) n/a
EPS (diluted) -0.89
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 5,757
Short Ratio 0.01
Short % of Float 0.02%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio n/a
Revenue n/a
Operating Income n/a
Net Income -37.69M
Free Cash Flow n/a
Net Cash 29.65M
Net Cash / Share 0.70
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-28.11-14.98
Net Income-27.57-14.68
Shares Outstanding1.931.62
Earnings Per Share-14.29-9.05
Operating Cash Flow-25.67-12.95
Capital Expenditures-0.78-0.53
Free Cash Flow-26.45-13.48
Cash & Equivalents18.8815.60
Total Debt0.26-
Net Cash / Debt18.6215.60
Book Value-49.41-22.69
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Prelude Therapeutics, Inc.
Country United States
Employees 51
CEO Krishna Vaddi

Stock Information

Ticker Symbol PRLD
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PRLD
IPO Date September 25, 2020


Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2 for multiple genomically selected cancers; and PRT-K4 for solid tumors. Prelude Therapeutics Incorporated was founded in 2016 and is based in Wilmington, Delaware.